+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2016-10-26Number of Pages: 183

Human Vaccines Market (Vaccine Type - Conjugate, Recombinant, Inactivated, Combination, and Attenuated; Product - Pneumococcal, Influenza, Hepatitis, HPV, Meningococcal, Rotavirus, Measles, Typhoid, and Combination; Age Group - Pediatrics, Adolescents, Adults, and Geriatrics; Distribution Channel - Hospital Pharmacies and Drugstores) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Human Vaccines Market: Snapshot

Vaccination has been promoted as a vital public health intervention across the globe for decades. According to the World Health Organization (WHO), vaccination has reduced the global burden of infectious disease to a great extent. An extremely low risk of serious and fatal side effects associated with vaccines and growing awareness regarding vaccination by various government and non-profit organizations are the key factors driving the human vaccines market.

The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. Extensive promotion and marketing strategies and favorable government support are likely to boost market growth.

Conjugates Dominate Human Vaccines Market by Type

On basis of vaccine type, the conjugate vaccines segment accounted for the majority share in the global human vaccines market in 2015. Prevnar, manufactured by Pfizer, Inc., is a conjugate vaccine, which generated a significant revenue of US$6.2 bn globally in 2015 alone. This is a key factor contributing to the dominance of conjugates in the human vaccine market. However, the growing preference for commercial brands available in the market is likely to drive the combination vaccines segment.

The pneumococcal segment accounted for the majority share in the global human vaccines market by product. A large number of products are commercially available in the market and the prevalence of pneumonia is high across several regions. These factors have been known to drive the pneumococcal segment.

By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Factors such as the high prevalence of pneumonia and polio among children across the world are likely to fuel this segment. On the other hand, adult vaccines are expected to expand at the highest CAGR from 2016 to 2024.

By distribution channel, the hospital pharmacies segment accounted for the lion’s share in the global human vaccines market. However, the drugstores segment is projected to expand at a considerable CAGR during the forecast period owing to a dramatically increasing vaccination rate in standalone pharmacies in the U.S.

 

human vaccines market

 

Strong Government Support Benefits Markets in APAC, LATAM, and Africa

North America was the dominant market for human vaccines in terms of revenue in 2015 owing to the growing demand for vaccination among adults and children. The market is also fueled by the increase in government efforts toward vaccination programs and the fact that most vaccines are available in the U.S.

Asia Pacific is expected to register the strongest growth in the market for human vaccines. Increasing government efforts toward immunization for various diseases such as polio, flu, rotavirus, and typhoid has been boosting the market. A massive population base is also likely to fuel market growth, especially in China and India. China is likely to dominate the Asia Pacific human vaccines market during the forecast period owing to a large population base and growing government support toward vaccination.

Brazil is likely to be the leading market for human vaccines in Latin America by 2024. A large population base, growing healthcare infrastructure, and a rise in subsidiaries for industry participants are the major factors boosting the human vaccines market in Brazil. GCC plays a significant role in the human vaccines market in the Middle East and Africa, as does South Africa. The market in Africa has been witnessing strong growth due to frequent outbreaks in the region, a rapid rise in vaccination programs, and increasing investments by major players.

Major players operating in the global human vaccines market include AstraZeneca, GlaxoSmithKline plc, Merck & Co. Inc., Pfizer, Inc., Sanofi, and Johnson & Johnson.

Human Vaccines Market: Scope and Methodology

This report provides in-depth region wise and country wise analysis of the human vaccines market. Stakeholders of this report include manufacturers of human vaccines products, raw material suppliers, vaccine processing companies, and new players planning to enter the market.

The report provides qualitative and quantitative analysis of the global human vaccines market. Qualitative analysis comprises market dynamics, trends, product overview, and country-level market information. Quantitative analysis includes market share held by companies in 2015, market size, and forecast for the global human vaccines market in major countries globally such as the U.S., Canada, Germany, France, United Kingdom, Italy, Spain, Japan, China, Brazil, Mexico, South Africa and GCC countries. Market revenue is provided in terms of US$ Mn from 2014 to 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 for all the segments, considering 2015 as the base year. The executive summary of the report provides a snapshot of the human vaccines with information on leading segments, country wise market information with respect to the market size, growth rate (CAGR %), and growth factors.

The market overview section comprises impact factors such as drivers, restraints, and opportunities for the global human vaccines market. These factors would aid the stakeholders in establishing a strong foothold in the global human vaccines market. Furthermore, the market overview section comprises key industry events, product overview, market attractiveness analysis and emerging trend in the human vaccines. The market attractiveness analysis provides a graphical view comparing the growth and market dynamics in various segments and country wise to identify the most attractive market. Market share analysis is also provided in the competitive landscape section of the report for the year 2015 in terms of value (%).

Human Vaccines Market: Segmentation

The human vaccines market has been segmented as vaccine type, products, age group, distribution channel and geography. Based on vaccine type, the market has been segmented into conjugate, recombinant, inactivated, combination, attenuated, and others. Likewise, on basis of product the market has been categorized into pneumococcal, influenza, hepatitis, HPV, meningococcal, rotavirus, measles and mumps, typhoid, combination and others. By age group the market is categorized into pediatrics, adolescent, adult and geriatrics. Hospital pharmacies, drugstores and others are included into the market by distribution channel

Geographically, the human vaccines market has been categorized into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Moreover, analysis for the major countries comprising U.S. Canada, Germany, U.K., France, Italy, Spain, Japan, China, Brazil, Mexico, and South Africa have also been provided in the report. A detailed qualitative analysis of the factors responsible for driving and restraining the growth of the human vaccines market in various regions has been provided in this section. This report also includes various ups and downs about particular country or geography that has impacted the overall market globally.

Human Vaccines Market: Competitive Landscape

The report provides a detailed outline/blueprint of the human vaccines market globally that will assist new companies in establishing their presence and market players in expanding their market share in the market. The report concludes with the company profile section which includes company overview, financial overview, SWOT analysis, product portfolio, business strategies and recent developments for market players. The major players that are profiled in the report include Major players operating in the global human vaccines market include AstraZeneca, GlaxoSmithKline plc, Merck & Co. Inc., Pfizer, Inc., Sanofi and Johnson & Johnson among others.

The global human vaccines market is segmented into the following categories:

Global human Vaccines Market, by Vaccine Type

  • Conjugate
  • Recombinant
  • Inactivated
  • Combination
  • Attenuated
  • Others

Global Human Vaccines Market, by Product

  • Pneumococcal
  • Influenza
  • Hepatitis
  • HPV
  • Meningococcal
  • Rotavirus
  • Measles and Mumps
  • Typhoid
  • Combination
  • Others

Global Human Vaccines Market, by Age Group

  • Pediatrics
  • Adolescents
  • Adults
  • Geriatrics

Global Human Vaccines Market, by Distribution Channel

  • Hospital Pharmacies
  • Drugstores
  • Others

Global Human Vaccines Market, by Geography

  • North America
    • U.S.
    • Canada
    • Europe
  • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific (APAC)
    • Japan
    • China
    • ASEAN
    • Rest of APAC
  • Latin America (LATAM)
    • Brazil
    • Mexico
    • Rest of LATAM
  • Middle East & Africa (MEA)
    • GCC
    • South Africa
    • Rest of MEA


 
 
Back To Top